EA201891427A1 - TARGET LIGANDS FOR THERAPEUTIC COMPOUNDS - Google Patents

TARGET LIGANDS FOR THERAPEUTIC COMPOUNDS

Info

Publication number
EA201891427A1
EA201891427A1 EA201891427A EA201891427A EA201891427A1 EA 201891427 A1 EA201891427 A1 EA 201891427A1 EA 201891427 A EA201891427 A EA 201891427A EA 201891427 A EA201891427 A EA 201891427A EA 201891427 A1 EA201891427 A1 EA 201891427A1
Authority
EA
Eurasian Patent Office
Prior art keywords
expression
compounds
target
targeting ligands
ligands disclosed
Prior art date
Application number
EA201891427A
Other languages
Russian (ru)
Inventor
Дэвид Б. Розема
Даррен Х. Вэйкфилд
Андрей В. Блохин
Джонатан Д. Бенсон
Чжэнь Ли
Тао Пэй
Фред Флейц
Original Assignee
Эрроухэд Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эрроухэд Фармасьютикалз, Инк. filed Critical Эрроухэд Фармасьютикалз, Инк.
Priority claimed from PCT/US2017/021175 external-priority patent/WO2017156012A1/en
Publication of EA201891427A1 publication Critical patent/EA201891427A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны новые нацеливающие лиганды, которые могут быть соединены с соединениями, такими как терапевтические соединения, которые можно применять для направления соединений на мишень in vivo. Нацеливающие лиганды, раскрытые в настоящем документе, могут служить для нацеливания ингибирующих экспрессию олигомерных соединений, таких как агенты РНКи, в клетки печени для модуляции экспрессии генов. Нацеливающие лиганды, раскрытые в настоящем документе, при конъюгировании с ингибирующим экспрессию олигомерным соединением, могут применяться в различных приложениях, включая применение в терапевтических, диагностических, связанных с валидацией мишеней и геномными исследованиями приложениях. Композиции, включающие нацеливающие лиганды, раскрытые в настоящем документе, будучи связанными с ингибирующими экспрессию олигомерным соединениями, способны опосредовать экспрессию целевых нуклеотидных последовательностей в клетках печени, таких как гепатоциты, что можно применять в ингибировании активности или экспрессии гена в клетке, ткани или организме.New targeting ligands are described that can be coupled to compounds, such as therapeutic compounds, that can be used to direct compounds to a target in vivo. The targeting ligands disclosed herein can serve to target expression inhibitory oligomeric compounds, such as RNAi agents, in liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression inhibitory oligomeric compound, can be used in a variety of applications, including therapeutic, diagnostic, target validation, and genomic research applications. Compositions including targeting ligands disclosed herein, when linked to expression inhibitory oligomeric compounds, are capable of mediating the expression of target nucleotide sequences in liver cells, such as hepatocytes, which can be used to inhibit gene activity or expression in a cell, tissue or organism.

EA201891427A 2016-11-28 2017-03-07 TARGET LIGANDS FOR THERAPEUTIC COMPOUNDS EA201891427A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662426916P 2016-11-28 2016-11-28
PCT/US2017/021175 WO2017156012A1 (en) 2016-03-07 2017-03-07 Targeting ligands for therapeutic compounds

Publications (1)

Publication Number Publication Date
EA201891427A1 true EA201891427A1 (en) 2019-07-31

Family

ID=67399663

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891427A EA201891427A1 (en) 2016-11-28 2017-03-07 TARGET LIGANDS FOR THERAPEUTIC COMPOUNDS

Country Status (1)

Country Link
EA (1) EA201891427A1 (en)

Similar Documents

Publication Publication Date Title
JOP20210207A1 (en) Targeting Ligands
JOP20210231A1 (en) Targeting Ligands For Therapeutic Compounds
PH12019500245A1 (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
BR112018012894A2 (en) Materials and Methods for Treatment of Amyotrophic Lateral Sclerosis and / or Frontotemporal Lobular Degeneration
EA201500394A1 (en) INHIBITORS DISTEMYLASE HYSTONES
EA201692318A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE ALPHA-1-ANTITRIPSINE GENE
BR112016020688A2 (en) COMPOSITIONS USEFUL IN THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC)
EA201792103A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES
EA201201648A1 (en) SGC STIMULATORS
BR112016013201A2 (en) administration, use and therapeutic applications of crisprec systems and genome editing compositions
MX343160B (en) Treatment of diseases.
MX2016002589A (en) Pharmaceutical composition having pyrimidine compound as active ingredient.
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
EA201692271A1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
MX2019006379A (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy.
UA117098C2 (en) Microrna compounds and methods for modulating mir-21 activity
EA201400990A1 (en) INHIBITORS DIACYLGLYCERINACYLTRANSFERASE 2
EA201590262A1 (en) COMBINED TREATMENT OF MELANOMA, INCLUDING THE INTRODUCTION OF COBIMETININAB AND VEMURAFENIB
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
BR112017016883A2 (en) compounds with antitumor activity
BR112015010196A2 (en) methods of treating liver disease
EA201891427A1 (en) TARGET LIGANDS FOR THERAPEUTIC COMPOUNDS
EA201891423A1 (en) AIMING LIGANDS
UA117563C2 (en) Composition for treating cancer associated with hpv infection
AR107824A1 (en) ADDRESSING LINKS FOR THERAPEUTIC COMPOUNDS